AvertD Post-Approval Study

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Prescient Medicine Holdings, Inc.
Study ID
NCT07135323
Status
Recruiting
Apply to this trial

Conditions

  • Opioid Use Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Opioid Used Disorder Risk Assessment — GENETIC
    Determine the likelihood of Opioid Used Disorder prior to prescribing opioids

Study Details

A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population

Key Dates

Start date
Nov 15, 2024
Status verified
Aug 2025
Primary completion
Nov 30, 2031
Completion
Nov 30, 2031

Study Design

Enrollment
4,000 participants (estimated)

Primary Outcome Measure

Sensitivity and Specificity of AvertD [ Time Frame: Measured over 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Concentrics ResearchIndianapolisIndiana46240-

Find similar trials in Indianapolis, IN

By research site
Concentrics Research· Indianapolis, IN

Related Studies